Abstract:The study conveyed by Min et al 1 grew out of the fact that, during the early part of the COVID-19 pandemic, British Columbia allowed the dispensation of additional full agonist opioids to patients who were also receiving opioid agonist treatment (methadone, buprenorphine, or slow-release oral morphine) for opioid use disorder. Patients who received additional opioids were rigorously propensity score matched to patients who did not receive additional opioids. The analysis used available administrative data from many different sources to provide convincing findings and conclusions that the receipt of additional opioids was strongly associated with better retention on opioid agonist treatment. This work addresses some of the more disconcerting challenges confronting clinicians during the opioid and overdose crisis currently plaguing North America. Despite some strong efforts by government, health care systems, individual clinicians, and researchers to solve the crisis, we seem to be sinking deeper into the crisis rather than extricating ourselves. Much of this failure can be ascribed to the advent of fentanyl and related molecules as the most widespread nonprescribed opioids used by individuals with opioid use disorder. 2 The phenomenology and pathophysiology of fentanyl use disorder seem substantially different from opioid use disorder related to most prescription opioids or heroin. Fentanyl was originally synthesized to serve as a potent, short-acting, parenteral opioid for use in a time-limited fashion to manage severe acute pain or anesthesia. It turns out that when fentanyl is used in the long term, tissue stores accumulate, essentially turning it into a long-acting agent. 3 So, in addition to the facts that it is far more potent than other typically used opioids, is easy to manufacture, and has become cheap and ubiquitous in many North American communities, with regular use fentanyl elimination appears to be prolonged. The US Food and Drug Administration has approved 3 pharmacologic treatments for opioid use disorder: methadone, buprenorphine, and naltrexone. (Canada has additional options, as Min et al 1 point out.) We know unequivocally that the former 2 medications reduce overdose and all-cause mortality associated with opioid use disorder, 4 and so deploying them widely and successfully represents one route out of the opioid crisis. However, the unique pharmacology of fentanyl poses greater challenges for initiating and stabilizing patients with these medications than previously experienced. In the case of methadone, itself a full μ-opioid agonist, the challenge revolves around fentanyl's potency. Because methadone has a long half-life and can accumulate over repeated doses, poor metabolizers, who cannot be identified clinically with currently available tools, can be at risk of an iatrogenic methadone overdose. For safety reasons, therefore, methadone has to be titrated upward very gradually under close clinical supervision to achieve a stabilizing dose. Given fentanyl's potency, patients who use it have extremely high opioid tolerance and will ultimately need high methadone doses to stabilize, but because these high doses cannot be attained quickly, patients initially tend to feel that the treatment is not helping them and either continue using dangerous amounts of fentanyl or, even worse, drop out of treatment early with increased risk of dying. Indeed, Min et al 1 note a recent decrease in retention in opioid agonist treatment in British Columbia. One challenge for starting buprenorphine, a partial μ-opioid agonist, resides in fentanyl's tissue accumulation. As a partial agonist, buprenorphine has the potential to cause precipitated opioid withdrawal when it replaces full agonists on the μ-receptors. For short-acting opioids, such as heroin, patients were asked to stop their use 12 to 24 hours before starting buprenorphine, and their readiness to make the transition without precipitated withdrawal could be determined by the presence of signs of moderate opioid withdrawal, indicating that receptors were now unbound to the short-acting, full agonist opioids and available for buprenorphine binding without displacement of the other opioid. With fentanyl it can take days with considerable subjective discomfort for such signs to emerge, or when they do emerge, a release of fentanyl from tissue stores again saturates receptors, setting the patient up for precipitated withdrawal. When patients experience precipitated withdrawal, which can be extremely uncomfortable, they tend to leave treatment before stabilization. Fentanyl's potency also creates problems with buprenorphine stabilization. For the available sublingual formulations, the package insert lists 24 mg/d as the maximum dose. This dose may be insufficient to stabilize some patients with high fentanyl-induced opioid tolerance. (The long-a -Abstract Truncated-

Renal impairment: a challenge for opioid treatment? The role of buprenorphine

Safe Use of Opioids in Chronic Kidney Disease and Hemodialysis Patients: Tips and Tricks for Non-Pain Specialists

Opioids and Traffic Safety – Focus on Buprenorphine

Buprenorphine for Chronic Pain Treatment and Elective Orthopaedic Surgery: a US National Database Analysis

Reconsidering the usefulness of long-term high-dose buprenorphine

Understanding the Partial Agonist: Treating Cancer Pain in Patients with a History of Opioid Use Disorder (OUD) on Buprenorphine (FR226C)

Opioids for chronic pain management in patients with dialysis-dependent kidney failure

The Impact Of Initiating & Discontinuing Buprenorphine On Patient Outcomes and Providing Quality Pain Management

Frontline Perspectives on Buprenorphine for the Management of Chronic Pain

Partial Agonist, Full Barrier: A Case-Based Discussion on Challenges with Buprenorphine in Chronic Pain Management

Case report: Successful induction of buprenorphine in medically complex patients concurrently on opioids: a case series at a tertiary care center

Low-dose buprenorphine initiation and treatment continuation among hospitalized patients with opioid dependence: A retrospective cohort study

Short-Acting, Full Agonist Opioids During Opioid Agonist Treatment

Buprenorphine: The Opioid that Cried 'Partial Agonist'

Pain, Substance Use Disorders, Mental Health, and Buprenorphine Treatment among Patients With and Without HIV

0494 Sleep Related Respiratory Events on Buprenorphine Compared to Naltrexone

Buprenorphine: two adolescent case reports of bridging the transmucosal form to the extended-release subcutaneous injectable form

Availability and Opportunities for Expansion of Buprenorphine for the Treatment of Opioid Use Disorder

Buprenorphine prescribing practices for older adults in 2019 and 2020

Opioid Maintenance Therapy: A Review of Methadone, Buprenorphine, and Naltrexone Treatments for Opioid Use Disorder

Buprenorphine Treatment for Opioid Use Disorder: An Overview